T1 mapping in cardiac MRIReport as inadecuate




T1 mapping in cardiac MRI - Download this document for free, or read online. Document in PDF available to download.

Heart Failure Reviews

, Volume 22, Issue 4, pp 415–430

First Online: 16 June 2017DOI: 10.1007-s10741-017-9627-2

Cite this article as: Radenkovic, D., Weingärtner, S., Ricketts, L. et al. Heart Fail Rev 2017 22: 415. doi:10.1007-s10741-017-9627-2

Abstract

Quantitative myocardial and blood T1 have recently achieved clinical utility in numerous pathologies, as they provide non-invasive tissue characterization with the potential to replace invasive biopsy. Native T1 time no contrast agent, changes with myocardial extracellular water edema, focal or diffuse fibrosis, fat, iron, and amyloid protein content. After contrast, the extracellular volume fraction ECV estimates the size of the extracellular space and identifies interstitial disease. Spatially resolved quantification of these biomarkers so-called T1 mapping and ECV mapping are steadily becoming diagnostic and prognostically useful tests for several heart muscle diseases, influencing clinical decision-making with a pending second consensus statement due mid-2017. This review outlines the physics involved in estimating T1 times and summarizes the disease-specific clinical and research impacts of T1 and ECV to date. We conclude by highlighting some of the remaining challenges such as their community-wide delivery, quality control, and standardization for clinical practice.

KeywordsT1 mapping Extracellular volume Myocardial disease 



Author: Dina Radenkovic - Sebastian Weingärtner - Lewis Ricketts - James C. Moon - Gabriella Captur

Source: https://link.springer.com/







Related documents